Preclinical study demonstrates that inhibiting tryptophan catabolism reshapes tuberculomas and improves immune control, highlighting IDO inhibition as a tuberculosis host-directed therapy.
T cells. Collectively, these results suggest that there exists a potential for using IDO inhibition as an effective and clinically relevant host-directed therapy for TB.
No takes yet. Share an insight, caveat, or question.
Gautam et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: